Abstract
A major obstacle to stem-cell gene therapy rests in the inability to deliver a gene into a therapeutically relevant fraction of stem cells1. One way to circumvent this obstacle is to use selection. Vectors containing two linked genes serve as the basis for selection, with one gene encoding a selectable product and the other, a therapeutic protein. Applying selection in vivo has the potential to bring a minor population of genetically corrected cells into the therapeutic range. But strategies for achieving in vivo selection have traditionally relied on genes that confer resistance to cytotoxic drugs2,3 and are encumbered by toxicity. Here we describe a new system for in vivo selection that uses a ‘cell-growth switch’, allowing a minor population of genetically modified cells to be inducibly amplified, thereby averting the risks associated with cytotoxic drugs. This system provides a general platform for conditionally expanding genetically modified cell populations in vivo, and may have widespread applications in gene and cell therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sorrentino, B.P. & Nienhuis, A.W. in The Molecular Basis of Blood Disease (eds Stamatoyannopoulos G., Majerus, P. & Varmus, H.) (W.B. Saunders, Philadelphia, in press).
Sorrentino, B.P. et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257, 99–103 (1992).
Allay, J.A. et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nature Med. 4, 1136–1143 (1998).
Spencer, D.M., Wandless, T.J., Schreiber, S.L. & Crabtree, G.R. Controlling signal transduction with synthetic ligands. Science 262, 1019–1034 (1993).
Blau, C.A., Peterson, K.R., Drachman, J.G. & Spencer, D.M. A proliferation switch for genetically modified cells. Proc. Natl Acad. Sci. USA 94, 3076–3081 (1997).
Jin, L., Asano, H. & Blau, C.A. Stimulating cell proliferation through the pharmacologic activation of c-kit. Blood 91, 890–897 (1998).
Souyri, M. et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63, 1137–1147 (1990).
Jin, L. et al. Targeted expansion of genetically modified bone marrow cells. Proc. Natl Acad. Sci. USA 95, 8093–8097 (1998).
Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl Acad. Sci. USA 95, 10437–10442 (1998).
Hodgson, G.S. Properties of haemopoietic stem cells in phenylhydrazine treated mice. Cell Tissue Kinet. 6, 199–208 (1973).
Cheng, L. et al. A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther. 4, 1013–1022 (1997).
Bjornson, C.R.R., Rietze, R.L., Reynolds, B.A., Magli, M.C. & Vescovi, A.L. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283, 534–537 (1999).
Pittenger, M.F. et al. Multilineage potential of adult human mesenchymal stem cells Science 284, 143–147 (1999).
Horwitz, E.M. et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Med. 5, 309–313 (1999).
Challita, P.M. & Kohn, D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl Acad. Sci. USA 91, 2567–2571 (1994).
Strathdee, C.A., Gavish, H., Shannon, W.R. & Buchwald, M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 356, 763 (1992).
Hawley, R.G., Lieu, F.H.L., Fong, A.Z.C. & Hawley, T.S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1, 136–138 (1994).
Acknowledgements
We thank T. Clackson, D. Thomis, F. Cerasoli and M. Gilman for supplying AP20187; K. Humphries for providing the MGIN producer cell line; R. Hawley for providing the MSCVneo and MGIN constructs; D. Persons and J. Ieremia for technical advice and assistance; and T. Clackson, T. Papayannopoulou, J. Abkowitz, K. Kaushansky, P. Martin, D. Russell and G. Stamatoyannopoulos for comments and suggestions regarding the manuscript. This work was supported by grants 5R01DK52997, 1R01DK57525, 2P01HL53750 and 2P01DK47754 from the National Institutes of Health, an American Society of Hematology Junior Faculty Scholar Award and an award from the Fanconi Anemia Research Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jin, L., Zeng, H., Chien, S. et al. In vivo selection using a cell-growth switch. Nat Genet 26, 64–66 (2000). https://doi.org/10.1038/79194
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/79194
This article is cited by
-
DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells
Biomarker Research (2019)
-
MicroRNAs promote skeletal muscle differentiation of mesodermal iPSC-derived progenitors
Nature Communications (2017)
-
Self-Destruct Genetic Switch to Safeguard iPS Cells
Molecular Therapy (2015)
-
Biological constraints limit the use of rapamycin-inducible FKBP12-Inp54p for depleting PIP2 in dorsal root ganglia neurons
Journal of Negative Results in BioMedicine (2013)
-
Long-term Regulation of Genetically Modified Primary Hematopoietic Cells in Dogs
Molecular Therapy (2011)